P/B
0,8
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
$265.4M
Market Cap • 10/9/2026
2016
(10 years)
Founded
2025
(1 year ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
4
EPS
—
Market Cap
Market Cap
265,4M
EV
42,2M
EV/Revenue
0
EV/EBITDA
-0,2
EV/EBIT
-0,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-140,9%
Total Yield
-140,9%
Payout
0%
Retained Earnings
-455,1M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
37,8%
Capex/OCF
-0,2%
SBC/OCF
—
% PPE
0,8%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
1,1
Debt/Equity
0%
Current Ratio
4,7
Quick Ratio
4,4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!